Quizartinib
- Generic Name
- Quizartinib
- Brand Names
- Vanflyta
- Drug Type
- Small Molecule
- Chemical Formula
- C29H32N6O4S
- CAS Number
- 950769-58-1
- Unique Ingredient Identifier
- 7LA4O6Q0D3
- Background
Quizartinib is an oral and potent fms-like tyrosine kinase 3 (FLT3) inhibitor and it is the first drug developed specifically targeting FLT3, as other agents with FLT3 inhibition activities were investigated with other targets in mind. Additionally, quizartinib also demonstrates inhibitory activity toward FLT3 with internal tandem duplication (ITD), although...
- Indication
Quizartinib is indicated in combination with standard cytarabine and anthracycline induction and cytarabine consolidation, and as maintenance monotherapy following consolidation chemotherapy, for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3 internal tandem duplication (ITD)-positive as detected by an FDA-appr...
- Associated Conditions
- Newly Diagnosed Acute Myeloid Leukemia (AML)
- Associated Therapies
- -
Combination of Quizartinib and Omacetaxine Mepesuccinate for AML Carrying FLT3-ITD
- Conditions
- Interventions
- First Posted Date
- 2017-05-01
- Last Posted Date
- 2020-12-10
- Lead Sponsor
- The University of Hong Kong
- Target Recruit Count
- 40
- Registration Number
- NCT03135054
- Locations
- ðŸ‡ðŸ‡°
The University of Hong Kong, Hong Kong, Hong Kong
Phase 2 Study of Quizartinib in Participants With Acute Myeloid Leukemia (AML) FLT3 Internal Tandem Duplication (FLT3/ITD) Mutation
- First Posted Date
- 2016-12-07
- Last Posted Date
- 2020-02-17
- Lead Sponsor
- Daiichi Sankyo Co., Ltd.
- Target Recruit Count
- 37
- Registration Number
- NCT02984995
Study of Quizartinib in Japanese Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
- Conditions
- Interventions
- First Posted Date
- 2016-07-15
- Last Posted Date
- 2021-08-19
- Lead Sponsor
- Daiichi Sankyo Co., Ltd.
- Target Recruit Count
- 7
- Registration Number
- NCT02834390
Quizartinib With Standard of Care Chemotherapy and as Continuation Therapy in Patients With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (AML)
- Conditions
- Interventions
- First Posted Date
- 2016-01-29
- Last Posted Date
- 2024-08-06
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 539
- Registration Number
- NCT02668653
- Locations
- 🇺🇸
University Hospitals Seidman Cancer Center, Cleveland, Ohio, United States
🇺🇸University of Florida (UF) Health Shands Hospital, Gainesville, Florida, United States
🇺🇸The University of Chicago Medical Center, Chicago, Illinois, United States
(QuANTUM-R): An Open-label Study of Quizartinib Monotherapy vs. Salvage Chemotherapy in Acute Myeloid Leukemia (AML) Subjects Who Are FLT3-ITD Positive
- First Posted Date
- 2014-01-20
- Last Posted Date
- 2021-02-24
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 367
- Registration Number
- NCT02039726
- Locations
- 🇺🇸
University of Southern California, Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Emory Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸University of Pennsylvania Health System, Philadelphia, Pennsylvania, United States
Quizartinib With Azacitidine or Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
- Conditions
- Interventions
- First Posted Date
- 2013-07-04
- Last Posted Date
- 2024-10-18
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 73
- Registration Number
- NCT01892371
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Developing and Treating a Mouse Model of Acute Myeloid Leukemia Using Tissue Samples From Younger Patients With Acute Myeloid Leukemia
- First Posted Date
- 2012-04-12
- Last Posted Date
- 2016-05-17
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 10
- Registration Number
- NCT01576185
- Locations
- 🇺🇸
Children's Oncology Group, Monrovia, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.